At Oxford BioMedica plc (OTC: OXBDF), the mission is to build a valuable, profitable biopharmaceutical company through the successful development and commercialization of breakthrough gene and cell-based medicines that improve the lives of patients. The company believes that gene therapy will become a mainstay of patient therapy in the future, and its long-term goal is to become a standalone, self-financing gene and cell therapy medical business with the capabilities and capacity to take its products through to market. For more information, visit the company’s website at www.oxfordbiomedica.co.uk.